Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
Abstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One we...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-04-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S134786131930091X |
id |
doaj-2559959b473d4538b6b2e6c4143a1dc9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoichi Sunagawa Shogo Sono Yasufumi Katanasaka Masafumi Funamoto Sae Hirano Yusuke Miyazaki Yuya Hojo Hidetoshi Suzuki Eriko Morimoto Akira Marui Ryuzo Sakata Morio Ueno Hideaki Kakeya Hiromichi Wada Koji Hasegawa Tatsuya Morimoto |
spellingShingle |
Yoichi Sunagawa Shogo Sono Yasufumi Katanasaka Masafumi Funamoto Sae Hirano Yusuke Miyazaki Yuya Hojo Hidetoshi Suzuki Eriko Morimoto Akira Marui Ryuzo Sakata Morio Ueno Hideaki Kakeya Hiromichi Wada Koji Hasegawa Tatsuya Morimoto Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats Journal of Pharmacological Sciences |
author_facet |
Yoichi Sunagawa Shogo Sono Yasufumi Katanasaka Masafumi Funamoto Sae Hirano Yusuke Miyazaki Yuya Hojo Hidetoshi Suzuki Eriko Morimoto Akira Marui Ryuzo Sakata Morio Ueno Hideaki Kakeya Hiromichi Wada Koji Hasegawa Tatsuya Morimoto |
author_sort |
Yoichi Sunagawa |
title |
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats |
title_short |
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats |
title_full |
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats |
title_fullStr |
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats |
title_full_unstemmed |
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats |
title_sort |
optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats |
publisher |
Elsevier |
series |
Journal of Pharmacological Sciences |
issn |
1347-8613 |
publishDate |
2014-04-01 |
description |
Abstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One week later, rats with a moderate severity of myocardial infarction (MI) were randomly assigned to 4 groups receiving the following: a solvent as a control, a low dose of curcumin (0.5 mg∙kg−1∙day−1), a medium dose of curcumin (5 mg∙kg−1∙day−1), or a high dose of curcumin (50 mg∙kg−1∙day−1). Daily oral treatment was continued for 6 weeks. After treatment, left ventricular (LV) fractional shortening was dose-dependently improved in the high-dose (25.2% ± 1.6%, P < 0.001 vs. vehicle) and medium-dose (19.6% ± 2.4%) groups, but not in the low-dose group (15.5% ± 1.4%) compared with the vehicle group (15.1% ± 0.8%). The histological cardiomyocyte diameter and perivascular fibrosis as well as echocardiographic LV posterior wall thickness dose-dependently decreased in the groups receiving high and medium doses. The beneficial effects of oral curcumin on the post-MI LV systolic function are lower at 5 compared to 50 mg∙kg−1∙day−1 and disappear at 0.5 mg∙kg−1∙day−1. To clinically apply curcumin therapy for heart failure patients, a precise, optimal dose-setting study is required. Keywords:: curcumin, heart failure, hypertrophy, dose-dependency, p300 |
url |
http://www.sciencedirect.com/science/article/pii/S134786131930091X |
work_keys_str_mv |
AT yoichisunagawa optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT shogosono optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT yasufumikatanasaka optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT masafumifunamoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT saehirano optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT yusukemiyazaki optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT yuyahojo optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT hidetoshisuzuki optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT erikomorimoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT akiramarui optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT ryuzosakata optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT morioueno optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT hideakikakeya optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT hiromichiwada optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT kojihasegawa optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats AT tatsuyamorimoto optimaldosesettingstudyofcurcuminforimprovementofleftventricularsystolicfunctionaftermyocardialinfarctioninrats |
_version_ |
1724957645524172800 |
spelling |
doaj-2559959b473d4538b6b2e6c4143a1dc92020-11-25T02:01:17ZengElsevierJournal of Pharmacological Sciences1347-86132014-04-011264329336Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in RatsYoichi Sunagawa0Shogo Sono1Yasufumi Katanasaka2Masafumi Funamoto3Sae Hirano4Yusuke Miyazaki5Yuya Hojo6Hidetoshi Suzuki7Eriko Morimoto8Akira Marui9Ryuzo Sakata10Morio Ueno11Hideaki Kakeya12Hiromichi Wada13Koji Hasegawa14Tatsuya Morimoto15Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka Saiseikai General Hospital, 1-1-1, Oshika, Suruga-ku, Shizuoka 422-8527, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, JapanShizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, JapanDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyo-ku, Kyoto 606-8507, JapanDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Teramachi-dori Hirokoji-dori agaru, Kamigyo-ku, Kyoto 602-8566, JapanDepartment of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto 606-8501, JapanDivision of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, JapanDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yata, Suruga-ku, Shizuoka 422-8526, Japan; Shizuoka General Hospital, 4-27-1, Kitaando, Aoi-ku, Shizuoka 420-8527, Japan; Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan; Corresponding author. morimoto@u-shizuoka-ken.ac.jpAbstract.: A natural p300-specific histone acetyltransferase inhibitor, curcumin, may have a therapeutic potential for heart failure. However, a study of curcumin to identify an appropriate dose for heart failure has yet to be performed. Rats were subjected to a left coronary artery ligation. One week later, rats with a moderate severity of myocardial infarction (MI) were randomly assigned to 4 groups receiving the following: a solvent as a control, a low dose of curcumin (0.5 mg∙kg−1∙day−1), a medium dose of curcumin (5 mg∙kg−1∙day−1), or a high dose of curcumin (50 mg∙kg−1∙day−1). Daily oral treatment was continued for 6 weeks. After treatment, left ventricular (LV) fractional shortening was dose-dependently improved in the high-dose (25.2% ± 1.6%, P < 0.001 vs. vehicle) and medium-dose (19.6% ± 2.4%) groups, but not in the low-dose group (15.5% ± 1.4%) compared with the vehicle group (15.1% ± 0.8%). The histological cardiomyocyte diameter and perivascular fibrosis as well as echocardiographic LV posterior wall thickness dose-dependently decreased in the groups receiving high and medium doses. The beneficial effects of oral curcumin on the post-MI LV systolic function are lower at 5 compared to 50 mg∙kg−1∙day−1 and disappear at 0.5 mg∙kg−1∙day−1. To clinically apply curcumin therapy for heart failure patients, a precise, optimal dose-setting study is required. Keywords:: curcumin, heart failure, hypertrophy, dose-dependency, p300http://www.sciencedirect.com/science/article/pii/S134786131930091X |